Enhanced Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes

Publication ID: 24-11857573_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes,” Published Technical Disclosure No. 24-11857573_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857573_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,573.

Summary of the Inventive Concept

This inventive concept presents a novel approach to restimulating cryopreserved tumor infiltrating lymphocytes (TILs), enhancing their metabolic fitness and bioenergetic profile, thereby improving their therapeutic potential.

Background and Problem Solved

The original patent disclosed a method for expanding TILs, but it has limitations in terms of the TILs' metabolic fitness and bioenergetic profile, which can impact their in vivo longevity and therapeutic efficacy. The new inventive concept addresses these limitations by introducing novel components and methods that enhance the TILs' metabolic fitness and bioenergetic profile.

Detailed Description of the Inventive Concept

The new inventive concept comprises a system, method, composition, and device for restimulating cryopreserved TILs. The system includes a cryopreservation unit, a thawing unit, and a restimulation protocol unit that applies a novel combination of cytokines to enhance the TILs' metabolic fitness. The method involves applying a controlled oxygen tension to the TILs during restimulation, improving their glycolytic capacity. The composition includes a cryopreserved TIL population, a novel glycolysis-promoting agent, and a mitochondrial metabolism-enhancing agent, optimized to enhance the TILs' bioenergetic profile. The device monitors the metabolic fitness of restimulated TILs, providing a readout of their oxygen consumption rate and glycolytic capacity.

Novelty and Inventive Step

The new claims introduce novel components and methods that enhance the TILs' metabolic fitness and bioenergetic profile, which are not disclosed in the original patent. The inventive step lies in the combination of these components and methods, which provides a synergistic effect on the TILs' therapeutic potential.

Alternative Embodiments and Variations

Alternative embodiments may include varying the cytokine combination, oxygen tension, and glycolysis-promoting agents to optimize the TILs' metabolic fitness. Variations may include using different types of TILs, such as those derived from different tumor types or sources.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the field of adoptive T-cell therapy, particularly for the treatment of bulky, refractory cancers. The target market includes pharmaceutical companies, research institutions, and hospitals involved in cancer treatment.

Field of Art

Cellular immunotherapy, specifically tumor infiltrating lymphocyte (TIL) manipulation, restoration, and cryopreservation techniques in oncological treatment

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced training in immunology, cell biology, and cancer therapeutics, possessing expertise in cell culture techniques, cryopreservation methods, and lymphocyte restimulation protocols

Obviousness Rationale

A person having ordinary skill would recognize that the PTD's proposed metabolic fitness enhancements represent predictable variations on the source patent's core TIL restimulation methodology. The disclosed techniques of controlled oxygen tension, cytokine combination, and metabolic monitoring are logical extensions of existing TIL expansion and preservation strategies. These variations would be considered routine optimization within the established framework of cellular immunotherapy research.

Obvious Combinations & Variations

Source Patent Element
Cryopreservation and thawing of tumor infiltrating lymphocytes
PTD Variation
Adding controlled oxygen tension during restimulation to improve glycolytic capacity
Obviousness Reasoning
Modifying cellular environment parameters is a known technique for enhancing lymphocyte performance, representing a predictable design choice for improving cell viability
Source Patent Element
First and subsequent TIL expansion protocols
PTD Variation
Introducing novel cytokine combinations to enhance metabolic fitness
Obviousness Reasoning
Optimizing cytokine protocols is a standard approach in immunotherapy, with finite predictable variations that a skilled practitioner would find obvious
Source Patent Element
TIL population harvesting and preparation
PTD Variation
Incorporating glycolysis-promoting and mitochondrial metabolism-enhancing agents
Obviousness Reasoning
Cellular metabolism enhancement represents a logical extension of existing TIL expansion techniques, using known biochemical interventions
Source Patent Element
TIL expansion and transfer methodology
PTD Variation
Implementing machine learning algorithms to predict TIL in vivo longevity
Obviousness Reasoning
Predictive modeling of cellular performance is a standard approach in biomedical research, representing an obvious technological progression
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857573 and the disclosed technical variations, a person having ordinary skill in the art would find the proposed TIL restimulation and metabolic enhancement techniques to be obvious variations of existing cellular immunotherapy methodologies. The incremental modifications represent predictable technological progressions that do not rise to the level of non-obvious innovation, thus rendering potential claims in this domain anticipated and obvious.

Original Patent Information

Patent NumberUS 11,857,573
TitleRestimulation of cryopreserved tumor infiltrating lymphocytes
Assignee(s)Iovance Biotherapeutics, Inc.